NCT04586790

Brief Summary

the study is developed to evaluate the effect of use of oral vasopressors (midodrine versus minirin) on weaning ICU patients from IV vasopressors (noradrenaline) and compare between them for efficacy in shortage the duration of IV vasopressor and has low complications and side effects.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
90

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Oct 2020

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

October 7, 2020

Completed
7 days until next milestone

First Posted

Study publicly available on registry

October 14, 2020

Completed
1 day until next milestone

Study Start

First participant enrolled

October 15, 2020

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2021

Completed
27 days until next milestone

Study Completion

Last participant's last visit for all outcomes

January 28, 2021

Completed
Last Updated

October 14, 2020

Status Verified

October 1, 2020

Enrollment Period

3 months

First QC Date

October 7, 2020

Last Update Submit

October 7, 2020

Conditions

Outcome Measures

Primary Outcomes (1)

  • liberation the patient from IV vasopressors with maintaining hemodynamics.

    Blood pressure will be assessed regularly every 15 minutes

    48 hrs

Study Arms (3)

midodrine group

EXPERIMENTAL

midodrine group will receive midodrine 10 mg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral midodrine

Drug: Midodrine Oral Tablet

minirin group

EXPERIMENTAL

the patients will receive minirin 60 µg PO q8hr with gradual weaning of IV noradrenaline after receiving 4 doses of oral minirin

Drug: Minirin oral tablet

control group

EXPERIMENTAL

the patients will receive IV nor-adrenaline and are gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .

Drug: Nor-Adrenaline

Interventions

midodrine group will receive midodrine 10 mg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral midodrine .

midodrine group

Minirin group will receive minirin 60 µg PO q 8 hr with gradual weaning of IV nor-adrenaline after receiving 4 doses of oral minirin .

minirin group

control group will receive IV nor-adrenaline and is gradually weaning from it according to routine hospital care without adding oral midodrine or oral minirin .

control group

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • Age of 18 - 60 years.
  • Patients of both genders.
  • Patients diagnosed by spinal shock and they are in the recovery stage .

You may not qualify if:

  • Patient refusal.
  • Anuric or oliguric patients or patients with chronic kidney disease.
  • Patients with allergy to medication included in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ahmed Talaat Ahmed

Asyut, Egypt

RECRUITING

MeSH Terms

Interventions

MidodrineDeamino Arginine VasopressinNorepinephrine

Intervention Hierarchy (Ancestors)

EthanolaminesAmino AlcoholsAlcoholsOrganic ChemicalsAminesArginine VasopressinVasopressinsPituitary Hormones, PosteriorPituitary HormonesPeptide HormonesHormonesHormones, Hormone Substitutes, and Hormone AntagonistsNeuropeptidesPeptidesAmino Acids, Peptides, and ProteinsOligopeptidesNerve Tissue ProteinsProteinsBiogenic MonoaminesBiogenic AminesCatecholaminesCatecholsPhenolsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbons

Study Officials

  • Ahmed T Ahmed, lecture

    Assiut University

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
clinical professor

Study Record Dates

First Submitted

October 7, 2020

First Posted

October 14, 2020

Study Start

October 15, 2020

Primary Completion

January 1, 2021

Study Completion

January 28, 2021

Last Updated

October 14, 2020

Record last verified: 2020-10

Data Sharing

IPD Sharing
Will not share

Locations